ABSTRACT
Background In central Ontario, influenza, respiratory syncytial virus (RSV), and invasive pneumococcal disease (IPD) follow similar seasonal patterns, peaking in winter. We aimed to quantify the independent and joint impact of influenza A, influenza B, and RSV on IPD risk at the population level.
Methods We used a 2:1 self-matched case-crossover study design to evaluate acute effects of respiratory virus activity on IPD risk. This design ensures that effects are not confounded by within-individual characteristics that remain constant over short periods of time. We included 3,892 IPD cases occurring between January 2000 and June 2009. Effects were measured using univariable and multivariable conditional logistic regression. Multivariable models included environmental covariates (e.g., temperature, absolute humidity, and UV index) and interaction terms between viruses.
Results Influenza A activity and influenza B activity were both independently associated with increased IPD risk; however, co-circulation of influenza A and B reduced the impact of both viruses. RSV activity was positively associated with increased IPD risk only in the presence of increased influenza A or influenza B activity.
Conclusions To our knowledge this represents the first study to consider the impact of interactions between these viruses on IPD risk in Canada. Our findings suggest that the prevention of IPD should be considered as a potential health benefit of influenza and RSV vaccination programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The doctoral training of AES is supported by an International Doctoral Scholarship from the Connaught Fund at the University of Toronto and a Pandemic Response and Resiliency Award from the Emerging and Pandemic Infections Consortium at the University of Toronto.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Board of the University of Toronto gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: The doctoral training of AES is supported by an International Doctoral Scholarship from the Connaught Fund at the University of Toronto and a Pandemic Response and Resiliency Award from the Emerging and Pandemic Infections Consortium at the University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Note: AES and ART were employed by the Public Health Agency of Canada while this work was conducted. This work does not represent the views of the Public Health Agency of Canada.
Data Availability
Data used in the present study are either publicly available or may be available upon reasonable request from the Toronto Invasive Bacterial Diseases Network.
